Evofem Biosciences, Inc.
SAN DIEGO, CA · CIK 0001618835 · Biotech · Public
Vaginal contraceptive gel with novel polymer delivery system
evofem.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $86M
- 11 Form D · Jul 2025
- 15 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 9
- 3 granted · 6 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20182019202020212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $6,300,000 | |
| Private capital raised | Form D · SEC | $30,000,001 | |
| Private capital raised | Form D · SEC | $15,000,000 | |
| Private capital raised | Form D · SEC | $25,000,000 | |
| Private capital raised | Form D · SEC | $2,307,693 | |
| Private capital raised | Form D · SEC | $1,384,616 | |
| Private capital raised | Form D · SEC | $2,884,615 | |
| Private capital raised· 1 of 2 same day | Form D · SEC | $500,000 | |
| Private capital raised· 2 of 2 same day | Form D · SEC | $500,000 | |
| Private capital raised | Form D · SEC | $750,000 | |
| Private capital raised | Form D · SEC | $925,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1784 | Sisu Pharma, Inc. | — | $1.7M |
| 1785 | Function Therapeutics, Inc. | — | — |
| 1786 | SmartLife, Inc. | — | $225K |
| 1787 | Evofem Biosciences, Inc. | — | $86M |
| 1788 | AGILE THERAPEUTICS INC | — | $81M |
| 1789 | Neurogastrx, Inc. | — | $80M |
| 1790 | Azafaros | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Russell BarransExecutive Officer
- Kelly CullwellExecutive Officer
- Kelly CulwellExecutive Officer
- Justin FileExecutive Officer
- Alexander FitzpatrickExecutive Officer
- Gillian GreerDirector
- William HallDirector
- Kim KamdarDirector
- Thomas LynchDirector
- Tony O'BrianDirector
- Tony O'BrienDirector
- Saundra PelletierDirector · Executive Officer
- Lisa RarickDirector
- Colin RutherfordDirector
- Jenny YipDirector
- Ivy ZhangExecutive Officer
Patents
- Method And Pharmaceutical Composition For Treating Or Preventing Trichomoniasis And Uses Thereofapplication
- Deuterated Secnidazole For Use In The Treatment Of Bacterial Vaginosis And Methods And Uses Thereofapplication
- Method And Pharmaceutical Composition For Treating Or Preventing Trichomoniasis And Uses Thereofgranted
- Deuterated Secnidazole For Use In The Treatment Of Bacterial Vaginosis And Methods And Uses Thereofgranted
- Deuterated Secnidazole For Use In The Treatment Of Bacterial Vaginosis And Methods And Uses Thereofapplication
- Compositions And Methods For Enhancing The Efficacy Of Contraceptive Microbicidesgranted
- Method Of Treatment And Prevention Of Bacterial Vaginosisapplication
- Method Of Treatment And Prevention Of Bacterial Vaginosisapplication
- Combination Gel For Sexually Transmitted Infectionsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.